Avenir Wellness Solutions Issues 2024 Marketing Growth Plans to Shareholders for Seratopical Revolution Skin Care Line with Support from Nicole Kidman and Facial Plastic Surgeon Dr. Michael Persky New TikTok Shop Ready for Launch to Help Grow Brand Awareness and Product Sales SHERMAN OAKS, CA / ACCESSWIRE / February 13, 2024 / Avenir Wellness Solutions, Inc . ("Avenir" or the "Company") (OTCQB:AVRW), a proprietary broad... Read More

SHERMAN OAKS, CA / ACCESSWIRE / September 19, 2023 / Avenir Wellness Solutions, Inc. (OTCQB:AVRW) ("Avenir" or the "Company"), a proprietary broad platform technology and wellness company, announced today that the trading of its common stock has been moved back to the OTC Market Group Inc.'s (the "OTC Market Group") OTCQB market (the "OTCQB"), effective as of September 15, 2023. As previously announced on April 19, 2023,... Read More

Persky To Also Join Brand's Medical Advisory Board for Future Innovation SHERMAN OAKS, CA / ACCESSWIRE / September 12, 2023 / The Sera Labs, Inc. ("Sera Labs"), a subsidiary of Avenir Wellness Solutions, Inc. ("Avenir" or the "Company") (OTC PINK: AVRW), a proprietary broad platform technology and wellness company, announced today that renowned plastic surgeon Dr. Michael A. Persky, M.D., F.A.C.S., has joined the Company as... Read More

SHERMAN OAKS, CA / ACCESSWIRE / August 15, 2023 / Avenir Wellness Solutions, Inc . (OTC PINK:AVRW) ("Avenir" or the "Company"), a proprietary broad platform technology and wellness company, today announced results for the second fiscal quarter ended June 30, 2023. Key operational highlights for the second quarter included the following: Net revenue in the second quarter of 2023 decreased slightly year-over-year and... Read More

New branding reflects Company's commitment to the future of wellness SHERMAN OAKS, CA / ACCESSWIRE / January 17, 2023 / CURE Pharmaceutical Holding Corp. (OTCQB:CURR) ("CURE" or the "Company"), a proprietary broad platform and wellness technology company, today announced that it has changed its name to "Avenir Wellness Solutions, Inc." ("Avenir Wellness") which will be the name for the company as a corporate entity. The name... Read More

Investment in New Marketing Strategies Showing Encouraging Early Results Enhanced Instagram & Media campaigns featuring Nicole Kidman highlighting Seratopical Revolution Incubator Strategy Initiated with New Market Disruptor Products arriving 1H2023 SHERMAN OAKS, CA / ACCESSWIRE / December 15, 2022 / CURE Pharmaceutical Holding Corp. (OTCQB:CURR) CEO Nancy Duitch is providing an update to its shareholders on positive recent... Read More

New Marketing Programs Showing Encouraging Early Results SHERMAN OAKS, CA / ACCESSWIRE / November 22, 2022 / CURE Pharmaceutical Holding Corp. (OTCQB:CURR) ("CURE" or the "Company"), a proprietary broad platform technology and wellness company, today announced results for the quarter ended September 30, 2022. Key operational highlights included the following: Revenue in the third quarter surged 32.1% year-over-year and 58.9%... Read More

Avenir Wellness Solutions, Inc. (f/k/a CURE Pharmaceutical Holding Corp.) (OTCQB: CURR) today announced that CEO Nancy Duitch will be attending the Q4 Investor Summit live in NYC at the Sheraton Times Square. The Company's presentation scheduled for 2:00pm EST on Monday, November 14, 2022, will highlight the Company's recent asset sale that provided non-dilutive capital to the Company and the related name change as well as... Read More

Cure Pharmaceutical Holding Corp. (OTCQB: CURR) ("CURE"), a broad wellness platform technology company that develops proprietary wellness, nutraceutical, and topical delivery systems, announced today that it will be presenting at the 12th annual Invitational on Tuesday October 25 at 12:30 PM Pacific Time (3:30 PM Eastern) at the Luxe Sunset Boulevard Hotel. Nancy Duitch, CEO will be giving the presentation. "15 years ago, we... Read More

Balance Sheet and Governance Strengthened with Asset Sale and Board Appointments New Marketing Programs Showing Encouraging Early Results CURE Pharmaceutical Holding Corp. (OTC: CURR) (“CURE”), a proprietary broad platform and wellness technology company, today announced results for the quarter ended June 30, 2022. Key operational highlights included the following: Gross revenue of $1.6 million reflected an increase of 31.2%... Read More

Rob Davidson brings a deep understanding of CURE pipeline, provides expertise in continued new product development, patent creation and continuity in non-dilutive on-going deal transactions and years of public company experience. Rob Costantino brings a unique combination of decades of financial expertise, investing experience and shareholder advocacy, operational experience, and many years of negotiating success in closing... Read More

CURE Pharmaceutical Holding Corp. (OTC: CURR) (“CURE”), a proprietary platform technology company, today announced that the Company hosted a shareholder call on Wednesday, August 3, 2022. On the recorded call/webcast, the executive management team provided details on the recent $20 million non-dilutive sale of a portion of its product and intellectual property portfolio and provided a full business update. As discussed on... Read More

CURE Pharmaceutical Holding Corp. (OTC: CURR) (“CURE”), a proprietary platform technology company, today announced the appointment of Gerald Bagg to its board of directors. This strategic addition adds depth in CPG and advertising and brings the number of board members to five. “With the increased prominence of CURE’s wholly-owned subsidiary, The Sera Labs, Inc., and the efforts we are undertaking to grow existing brands as... Read More

CURE Pharmaceutical Holding Corp. (OTC: CURR) (“CURE”), a proprietary platform technology company, today announced that the Company will be hosting a teleconference with management on Wednesday, August 3, 2022, at 5:00 pm Eastern Time to discuss the recent $20 million non-dilutive sale of a small portion of its product and intellectual property portfolio and to provide a business update. As a business update we would like to... Read More

CURE Pharmaceutical Holding Corp . (OTC: CURR) (“CURE”), a proprietary platform technology company, today announced that it has sold a portion of its platform technology intellectual property and related assets for $20 million in total consideration. CURE used a portion of the cash proceeds to pay down certain debt obligations and the balance will be used to grow its intellectual property portfolio and its wellness and... Read More

CURE’s Patented and Proprietary OTF Vitamin D Found to be More Effective than Standard Supplementation in Achieving pre- and post-Surgery Vitamin D Sufficiency Necessary to Reduce Immune-Mediated Damage such as Graft Versus Host Disease (GVHD) CCHMC to Seek Formulary approval for CURE’s OTF Vitamin D Supplement in its Hospital Formulary CURE Pharmaceutical Holdings (OTC: CURR), a developer and manufacturer of innovative... Read More

Sera Labs , a wholly subsidiary of CURE Pharmaceutical Holding Corp. (OTC: CURR), today announced its Seratopical Revolution skincare line will be sold at select Walmart Stores, as well as CVS, and Bed Bath & Beyond stores. Sera Labs also has garnered placement for its revolutionary oral thin film strip, Nutri-Strips ™ on shelves at CVS and at Target.com. The Nutri-Strip technology is proprietary to Sera Labs and is the... Read More

Cure Pharmaceutical (OTC: CURR) a developer and manufacturer of innovative delivery formulations for drugs, supplements and wellness products, and Milagro Pharmaceuticals, which seeks first mover advantage in target heath & wellness markets through key collaborations, today announced their collaboration to register and sell in Mexico a number of CURE’s OTC and medical compounds that utilize CUREform™, CURE’s patented drug... Read More

The Sera Labs, a wholly owned subsidiary of CURE Pharmaceutical Holdings (OTCQB: CURR) today announced its global expansion into Canada by engaging Northern Response International for the exclusive distribution of the entire plant-based, clean Seratopical Revolution® skin care line, which comprises stellar packaging,... Read More

CURE Pharmaceutical Holding Corp. (OTC: CURR), today announced results for the quarter ended June 30, 2021, including the following highlights: Revenue of $2.1 million reflected an increase of nearly 700% from a year ago Gross profit rose 676% to $1.31 million compared to 2Q 2020 Net loss from operations of $3.27 million improved substantially compared to a net loss from operations of $13.47 million a year ago Operational... Read More

CURE Pharmaceutical Holding Corp. (OTC: CURR), a technology focused, vertically integrated drug delivery and product development company in the pharmaceutical and health & wellness markets, announced today that its Chief Business Officer Jonathan Berlent will participate in a virtual presentation at the H.C. Wainwright Psychedelics in Psychiatry and Beyond Virtual Conference on Thursday, June 17. "The potential therapeutic... Read More

Sera Labs , a subsidiary of CURE Pharmaceutical Holding Corp. (OTC: CURR), announced today a new ad campaign and launch of Seratopical Revolution, a new clean, plant-based, technologically advanced, anti-aging, ‘revolutionary,’ beauty line. The line touts 11 luxurious products which are all are made in the U.S., available at... Read More

CURE Pharmaceutical Holding Corp. (OTC: CURR), a vertically integrated drug delivery and product development company, today announced that it will hold a webcast with the investment community on Thursday, May 27, at 5 p.m. Eastern Daylight Time. Rob Davidson, CEO of CURE Pharmaceutical Holding (OTCQB: CURR), Nancy Duitch, CEO of wholly-owned subsidiary The Sera Labs and Chief Strategy Officer for the Company, and management... Read More

CURE Pharmaceutical Holding Corp. (OTC: CURR), a vertically integrated drug delivery and product development company, reported its financial results and provided an operational update for the first quarter ended March 31, 2021. First Quarter 2021 and subsequent weeks highlights: Total revenue rose more than 400% to $1.5 million compared with a year ago and gross profit rose in line with revenue growth. Received approval for... Read More

CURE Pharmaceutical Holding Corp. (“CURE” or the “Company”) (OTC: CURR), a vertically integrated drug delivery and product development company, announced today that it has secured International Organization for Standardization (ISO) 9001 certification for its Oxnard, Calif., manufacturing and research facility. ISO 9001 certification recognizes excellence in quality management standards of an organization that places an... Read More

Sera Labs , a subsidiary of CURE Pharmaceutical Holding Corp. (OTC: CURR), headlined Collision 2021 and discussed the changing landscape of beauty, health and wellness. Academy Award, Golden Globe and Emmy Award-winning actor/producer/entrepreneur Nicole Kidman and Nancy Duitch, Founder/CEO Sera Labs/CURE Pharmaceutical Chief Strategic Officer kept the 40,000 attendee conference engaged in a funny, smart and energetic... Read More

CURE Pharmaceutical Holding Corp. (“CURE” or the “Company”) (OTC: CURR), a technology focused, vertically integrated specialty pharmaceutical company, announced today successful results from its initial Pharmacokinetics (PK)/bioequivalence studies. CURE will now advance its clinical program with the objective of U.S. Food and Drug Administration (FDA) approval. CUREfilm Blue™ utilizes the Company’s patented and proprietary... Read More

Sera Labs , a subsidiary of CURE Pharmaceutical Holding Corp. (OTC: CURR), announced today that Academy Award, Golden Globe and Emmy Award-winning actor/producer/entrepreneur Nicole Kidman and Sera Labs CEO/CURE Pharmaceutical Chief Strategic Officer, Nancy Duitch will headline Collision 2021. Collision is North America’s fastest-growing tech conference and brings together the world’s most sought-after founders, tech... Read More

CURE Pharmaceutical Holding Corp. (OTC: CURR), a vertically integrated drug delivery and product development company, reported its financial and operating results for the year ended Dec. 31, 2020, and provided recent operational highlights. The Company's total revenue of $2.1 million rose 229% compared to fiscal year 2019. On a pro forma basis, which includes full year revenue generated from CURE’s wholly owned subsidiary... Read More

CURE Pharmaceutical Holding Corp. (“CURE” or the “Company”) (OTC: CURR), a vertically integrated drug delivery and product development company, announced today that it has secured an extension to its Schedule I U.S. Drug Enforcement Agency (DEA) license that will allow the Company to conduct research on psychedelics-based pharmaceuticals using compounds such as LSD, MDMA, and psilocybin as potential treatments for various... Read More

CURE Pharmaceutical Holding Corp. ( “CURE” or the “Company”) (OTC: CURR), a vertically integrated drug delivery and product development company, announced today that it has launched a new initiative for the clinical development of psychedelic compounds such as psilocybin, LSD, and MDMA for the treatment of various mental health disorders. Utilizing CURE’s patented oral film platform CUREfilm® for precision dosing, the... Read More

CURE Pharmaceutical Holding Corp. (“CURE” or the “Company”) (OTC: CURR), a vertically integrated drug delivery and product development company, announced today that it has launched two new clinical development programs and added new corresponding products to its growing pharmaceutical pipeline. The first is an antiviral clinical development program where the Company will look to load a known active pharmaceutical ingredient... Read More

CURE Pharmaceutical Holding Corp . (“CURE” or the “Company”) (OTC: CURR), a technology focused, vertically integrated drug delivery and product development company in the pharmaceutical and health & wellness space today announced that its subsidiary Sera Labs has launched a robust national advertising campaign for its Nutri-Strips thin-film product Sleep A.S.A.P.™ which offers a solution to America’s sleep problem. The... Read More

CURE Pharmaceutical Holding Corp. (“CURE” or the “Company”) (OTC: CURR), a technology focused, vertically integrated drug delivery and product development company in the pharmaceutical and health & wellness space, announced this week’s start of its initial Pharmacokinetics (PK)/bioequivalence studies in support of a previously approved Investigational New Drug (IND) application with the U.S. Food and Drug Administration... Read More

CURE Pharmaceutical Holdings (“CURE” or the “Company”) (OTC: CURR), a holding company focused on the innovation of pharmaceutical technology, wellness products and drug delivery, announced today updates and additions to its Board of Directors. After a dedicated run as Chairman of the Board, William Yuan is stepping down and will continue to serve the Company as an advisor and Chairman Emeritus. Rubén José King-Shaw Jr, a... Read More

According to the National Institute of Health (NIH) more than 50 percent of people worldwide have Vitamin D insufficiency. In response, Sera Labs, Inc., a wholly owned subsidiary of CURE Pharmaceutical Holdings (OTCQB: CURR), announced today that it is unveiling “ ImmunD₃ ,” a convenient, science-backed oral thin-film that provides a weekly dose of Vitamin D (40,000 IU) as a part of its Nutri-Strips™ line of novel and... Read More

The retailers have spoken! Sera Labs, Inc . , the wholly owned subsidiary of CURE Pharmaceutical Holdings (OTCQB: CURR), announced today they have won the coveted Retail Excellence (REX Award) for Natural Products. The Rex Awards have a long history of recognizing, and honoring category leaders in the industry. Sera Labs, the premiere health, wellness and anti-aging CBD and plant-based skincare company beat out hundreds of... Read More